Core Insights - Harbour BioMed has announced an update on its strategic collaboration with AstraZeneca, which was initially established in March 2025 [1][4] - The collaboration focuses on the discovery and development of next-generation biotherapeutics, including antibody-drug conjugates and T cell engagers [2][5] Collaboration Details - AstraZeneca will nominate discovery programs to Harbour BioMed annually over the next four years, with the option to license these programs for further development [3][6] - Harbour BioMed is set to receive up to $175 million in upfront and milestone payments, along with potential additional payments of up to $4.4 billion and tiered royalties on future net sales [6][7] - AstraZeneca will acquire 9.15% of the newly issued shares of Harbour BioMed as part of the collaboration [7] Financial Framework - The economic terms of the collaboration are consistent with the financial framework established in March 2025 [4] - The collaboration includes a $105 million equity investment by AstraZeneca in Harbour BioMed [5] Future Prospects - The initial phase will focus on ongoing research programs, with the potential for additional programs to be included over the next five years [6][7] - There is an option to extend the terms of the agreement for an additional five years upon mutual agreement [7]

Core Insights - Harbour BioMed has advanced its global strategic collaboration with AstraZeneca to develop next-generation biotherapeutics, including antibody-drug conjugates and T cell engagers, leveraging both companies' expertise [1][3] Collaboration Details - AstraZeneca will nominate discovery programs to Harbour BioMed annually over the next four years, with the option to license these programs for further development. Harbour BioMed will receive option fees, milestone payments, and tiered royalties on future net sales [2] Company Background - Harbour BioMed is a global biopharmaceutical company focused on discovering and developing novel antibody therapeutics in immunology and oncology, building a robust pipeline through internal R&D, strategic collaborations, and selective acquisitions [4] Technology Platform - The company utilizes its proprietary Harbour Mice technology to generate fully human monoclonal antibodies in various formats, enabling the development of innovative biologics for treating significant medical needs [5]